Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
about
Potential Use of Biological Proteins for Liver Failure TherapyCurrent and future therapies for hepatitis C virus infection: from viral proteins to host targets.A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection.Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection.Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.Direct and cytokine-mediated effects of albumin-fused growth hormone, TV-1106, on CYP enzyme expression in human hepatocytes in vitro.
P2860
Q26781325-C736551A-C618-443F-8B10-8BA5B06977D3Q38131681-3F9385F3-F3A4-4E1E-8FB2-06F7355F7C52Q38397145-F25D0A39-FF73-44FB-9157-941A4E3E0B36Q40445667-5AA13457-DFCE-4F58-85A4-419FE0558B16Q42208120-62F71036-ED6F-496C-951C-7B03E7B231C0Q45352196-0B15504C-0808-495B-8648-817205B55E1BQ55272215-E2DA89B4-07C9-46EE-83B2-CA0F7BF103A7
P2860
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@en
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@nl
type
label
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@en
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@nl
prefLabel
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@en
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@nl
P2093
P2860
P1476
Randomized trial of albinterfe ...... epatitis C virus genotype 2/3.
@en
P2093
B2202 Study Team
G R Foster
I M Jacobson
J Rasenack
P2860
P304
P356
10.1111/J.1365-2893.2012.01586.X
P577
2012-03-21T00:00:00Z